Amgen, J&J settle lawsuit over Stelara biosimilar
Michael Vi

Amgen (NASDAQ:AMGN) and Johnson & Johnson (JNJ) have settled patent litigation regarding the former's plan to make a biosimilar version of Janssen's Stelara (ustekinumab).
Details of the settlement were not disclosed.
The case was first filed by J&J (JNJ) subsidiary Janssen Biotech in a Delaware federal court in November 2022.

Amgen (AMGN) will be allowed to sell its ustekinumab biosimilar no later than Jan. 1, 2025, a company spokesperson told Reuters.
In Q1 2023, J&J (JNJ) reported worldwide Stelara sales of ~$2.4B, a 6.8% increase compared to the prior-year period.

More on Stelara biosimilars

Alvotech, Teva get FDA review for biosimilar to J&J's Stelara
Amgen's biosimilar candidate to Stelara shows no clinically meaningful differences in study